ATE503492T1 - Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 - Google Patents

Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Info

Publication number
ATE503492T1
ATE503492T1 AT03789346T AT03789346T ATE503492T1 AT E503492 T1 ATE503492 T1 AT E503492T1 AT 03789346 T AT03789346 T AT 03789346T AT 03789346 T AT03789346 T AT 03789346T AT E503492 T1 ATE503492 T1 AT E503492T1
Authority
AT
Austria
Prior art keywords
hpv16
vaccines against
hpv type
oncogenic hpv
hpv18 vlps
Prior art date
Application number
AT03789346T
Other languages
German (de)
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef Slaoui
M A C Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE503492T1 publication Critical patent/ATE503492T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03789346T 2002-12-20 2003-12-18 Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 ATE503492T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20
PCT/EP2003/014562 WO2004056389A1 (en) 2002-12-20 2003-12-18 Hpv-16 and -18 l1 vlp vaccine

Publications (1)

Publication Number Publication Date
ATE503492T1 true ATE503492T1 (de) 2011-04-15

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789346T ATE503492T1 (de) 2002-12-20 2003-12-18 Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Country Status (28)

Country Link
US (2) US20060251676A1 (OSRAM)
EP (1) EP1572233B1 (OSRAM)
JP (1) JP5475939B2 (OSRAM)
KR (3) KR101361769B1 (OSRAM)
AP (1) AP2005003347A0 (OSRAM)
AR (1) AR042530A1 (OSRAM)
AT (1) ATE503492T1 (OSRAM)
AU (1) AU2003293942B2 (OSRAM)
BE (3) BE2015C067I2 (OSRAM)
BR (1) BR0317544A (OSRAM)
CA (1) CA2510457C (OSRAM)
CY (1) CY1111552T1 (OSRAM)
DE (1) DE60336581D1 (OSRAM)
DK (1) DK1572233T3 (OSRAM)
EA (2) EA009179B1 (OSRAM)
EC (1) ECSP055869A (OSRAM)
IL (1) IL169085A (OSRAM)
IS (1) IS2811B (OSRAM)
MA (1) MA27581A1 (OSRAM)
MX (1) MXPA05006764A (OSRAM)
MY (1) MY144492A (OSRAM)
NO (1) NO20052846L (OSRAM)
NZ (1) NZ540811A (OSRAM)
OA (1) OA13147A (OSRAM)
PL (1) PL215257B1 (OSRAM)
PT (1) PT1572233E (OSRAM)
TW (1) TWI349557B (OSRAM)
WO (1) WO2004056389A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666060A1 (en) * 1998-10-16 2006-06-07 Glaxosmithkline Biologicals S.A. Adjuvant systems and vaccines
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
AU2006239471A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
EA013326B1 (ru) * 2005-04-26 2010-04-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
DK2154147T3 (en) 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
EP2147926B1 (en) 2007-04-29 2016-08-24 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
CA2754533C (en) * 2009-03-05 2019-07-09 Jenny Colleen Mccloskey Treatment of infection
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
WO2016065281A1 (en) 2014-10-24 2016-04-28 Tim Ioannides Cancer and skin lesion treatment
RU2721417C2 (ru) * 2015-06-02 2020-05-19 Терумо Кабусики Кайся Адъювантная композиция, содержащая алюминий, и содержащая ее вакцинная композиция
WO2019173465A1 (en) * 2018-03-06 2019-09-12 Intrexon Corporation Human papillomavirus vaccines and uses of the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
JP7265563B2 (ja) * 2018-06-04 2023-04-26 シアメン ユニバーシティ ヒトパピローマウイルス１８型のｌ１タンパク質の変異体
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
DE69835294T2 (de) 1997-09-05 2007-07-26 Medimmune, Inc. Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps)
DK1150712T3 (da) * 1999-02-05 2009-02-02 Merck & Co Inc Vaccineformuleringer mod human papillomavirus
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DK1296711T3 (da) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus

Also Published As

Publication number Publication date
DK1572233T3 (da) 2011-06-27
AU2003293942B2 (en) 2009-12-10
HK1085378A1 (en) 2006-08-25
IS2811B (is) 2012-11-15
TW200423957A (en) 2004-11-16
JP5475939B2 (ja) 2014-04-16
MXPA05006764A (es) 2005-09-08
AP2005003347A0 (en) 2005-06-30
KR20120123616A (ko) 2012-11-08
AR042530A1 (es) 2005-06-22
AU2003293942A1 (en) 2004-07-14
US20060251676A1 (en) 2006-11-09
US20050287161A1 (en) 2005-12-29
EP1572233A1 (en) 2005-09-14
DE60336581D1 (de) 2011-05-12
MA27581A1 (fr) 2005-10-03
EA200701633A1 (ru) 2007-12-28
IL169085A0 (en) 2007-07-04
WO2004056389A1 (en) 2004-07-08
IL169085A (en) 2014-04-30
PL377710A1 (pl) 2006-02-06
NZ540811A (en) 2007-03-30
KR20120118087A (ko) 2012-10-25
EP1572233B1 (en) 2011-03-30
JP2006512413A (ja) 2006-04-13
ECSP055869A (es) 2005-09-20
IS7885A (is) 2005-06-09
BR0317544A (pt) 2005-11-22
CA2510457C (en) 2011-12-06
BE2015C069I2 (OSRAM) 2024-08-08
PT1572233E (pt) 2011-06-07
PL215257B1 (pl) 2013-11-29
BE2015C068I2 (OSRAM) 2024-08-08
BE2015C067I2 (OSRAM) 2024-08-08
NO20052846L (no) 2005-07-13
KR20050086924A (ko) 2005-08-30
EA200500834A1 (ru) 2006-02-24
CY1111552T1 (el) 2015-08-05
KR101361769B1 (ko) 2014-02-10
CA2510457A1 (en) 2004-07-08
OA13147A (en) 2006-12-13
EA009179B1 (ru) 2007-12-28
TWI349557B (en) 2011-10-01
MY144492A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
ATE503492T1 (de) Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
AP1872A (en) Virus-like particles of human papillomavirus.
NO2012016I2 (no) Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler
EP1660678A4 (en) MUTANT ADENO-ASSOCIATED VIRUS VIRUSES AND METHOD OF USE THEREOF
ATE471148T1 (de) Medizinische verwendung eines tetrahydrotriazoloä4,3-aüpyrazins
CY2015050I1 (el) Βελτιστοποιημενη εκφραση της hpv 45 l1 σε ζυμη
DE602004032140D1 (de) Behandlungsvorrichtung mit verwendung von ausgangsstoffgas und reaktivem gas
ATE323509T1 (de) Impfstoff gegen hbv und hpv
DE69631246D1 (de) Rekombinante pockenviren des waschbaers sowie ihre verwendung als ein effektiver impfstoff gegen eine infektion mit immunschwaecheviren der katze
ATE358129T1 (de) 1,2,3,4,7,8-hexahydro-6h-c1,4)diazepinoc6,7,1- 1j)chinolinderivative als antipsychotika und mittel gegen obesitas
DE60304188D1 (de) Ä1,4ÜDIAZOCINOÄ7,8,1-hiÜINDOLDERIVATE ALS ANTIPSYCHOTISCHE MITTEL UND MITTEL GEGEN OBESITÄT
HUS1500060I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
ATE428417T1 (de) Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren
NO20044398L (no) Fotokatalysatorer inneholdende titanoksyd, samt fremgangsmate og anvendelse derav
DE50210920D1 (de) Verwendung von Aluminiumchlorohydrat in Deodoranten und Antiperspiranten
DE60302848D1 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
HRP20080447T3 (en) 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
PL1758609T3 (pl) Szczepionka przeciw HPV16 i HPV18 oraz co najmniej jednemu HPV innego typu wybranemu spośród HPV 31, 45 lub 52
EP1532254A4 (en) VIRUS-FREE HELPER HERPESVIRUS AMPLICON PARTICLES AND ITS USES
DE602005018236D1 (de) Verwendung von aromasubstanzmischungen als mittel gegen schlechten atem
EP1322761A4 (en) HUMANIZED ANTIBODY AGAINST THE HEPATITE B VIRUS SURFACE ANTIGEN AND METHOD OF PREPARING THE SAME
DE60237181D1 (de) Kosmetische Zusammensetzung und Methode um farbentwickelnde Zubereitungen in Kosmetika zu benutzen
ATE456568T1 (de) Kondensierte heterocyclische isoxazolinderivate und deren verwendung als antidepressiva
FI20020375A7 (fi) Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572233

Country of ref document: EP